Last reviewed · How we verify
Livmarli — Competitive Intelligence Brief
marketed
Ileal sodium/bile acid cotransporter
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Livmarli (Livmarli) — Mirum Pharmaceuticals, Inc..
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Livmarli TARGET | Livmarli | Mirum Pharmaceuticals, Inc. | marketed | Ileal sodium/bile acid cotransporter | ||
| Livmarli | maralixibat hydrochloride | Mirum Pharma Inc | marketed | Ileal Bile Acid Transporter Inhibitor | Ileal sodium/bile acid cotransporter | 2021-01-01 |
| Bylvay | ODEVIXIBAT | Ipsen | marketed | Ileal Bile Acid Transporter Inhibitor [EPC] | Ileal sodium/bile acid cotransporter | 2021-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Livmarli · 11260053 · US
- — Livmarli · 11376251 · US
- — Livmarli · 11497745 · US
- — Livmarli · 11229647 · US
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Livmarli — Competitive Intelligence Brief. https://druglandscape.com/ci/livmarli. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab